Once a treatment for a neonatal disorder is approved, it undergoes continuous monitoring to ensure its safety and efficacy. This is known as post-market surveillance. Regulatory bodies require healthcare providers to report any adverse events or unexpected outcomes. This data is crucial for ongoing [risk management]() and for making necessary adjustments to treatment protocols.
